High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
Some patients undergoing radiotherapy for cancers of the head, neck, and brain are at risk for endocrinopathies. This article reviews the risks, detection, and management of radiotherapy-induced hypopituitarism.
Recent studies show the evidence continues to support exercise and holistic measures as the most effective intervention for cancer-related fatigue.
Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.
Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|